Company intelligence / Profile preview
Syndeio Biosciences
Indianapolis, Indiana, USAsyndeio.bio ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Syndeio Biosciences has launched with over $90 million in funding to pioneer precision neurotherapeutics targeting synaptic repair and enhancement. Its lead asset, zelquistinel, a next-generation NMDA receptor modulator originally developed at Naurex, is in Phase II trials for major depressive disorder and will soon enter a biomarker-driven trial in Alzheimer’s disease. Apimostinel, another program, is also in Phase II for acute depression. The company leverages the proprietary Boost™ platform to optimize drug candidates that restore neural connectivity through event-driven pharmacology. The team includes experienced neurotherapeutics entrepreneurs and Nobel laureate Thomas C. Südhof as co-founder.[1][4][6]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
AbbVie (strategic shareholder, licensor of zelquistinel)Eli Lilly (strategic shareholder)
Beyond the preview
Go deeper on Syndeio Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syndeio Biosciences.